Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in:

23.09.2022 | Hepatobiliary Tumors

A Practical Risk Classification of Early Recurrence in Hepatocellular Carcinoma Patients with Microvascular invasion after Hepatectomy: A Decision Tree Analysis

verfasst von: Long-Hai Feng, MD, PhD, Yu-Yao Zhu, MD, MM, Jia-Min Zhou, MD, PhD, Miao Wang, MD, MM, Lei Wang, MD, PhD, Wei-Qi Xu, MD, PhD, Ti Zhang, MD, PhD, An-Rong Mao, MD, PhD, Wen-Ming Cong, MD, PhD, Hui Dong, MD, PhD, Lu Wang, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was designed to establish risk classifications for early recurrence in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI) after hepatectomy.

Methods

The data of 563 HCC patients with MVI after hepatectomy from two hospitals were retrospectively reviewed. Kaplan–Meier curves and Cox proportional hazards regression models were used to analyse early recurrence. The risk classification for early recurrence was established by using classification and regression tree (CART) analysis and validated by using two independent validation cohorts from two hospitals.

Results

Multivariate analysis revealed that four indices, namely, infection of chronic viral hepatitis, MVI classification, tumour size, and serum alpha-fetoprotein (AFP), were independent prognostic factors for early recurrence in HCC patients with MVI. By CART analysis, MVI classification and serum AFP became the nodes of a decision tree and 3-stratification classifications that satisfactorily determined the risk of early recurrence were established. The area under the time-dependent receiver operating characteristic curve (AUC) values of the classification for early recurrence at 0.5, 1.0, and 2.0 years were 0.75, 0.73, and 0.71, respectively, which were all significantly higher than three common classic HCC stages (BCLC stage, Chinese stage, and TNM stage). The calibration curves showed good agreement between predictions by classification for early recurrence and actual survival outcomes. These prediction results also were confirmed in the independent internal and external validation cohorts.

Conclusions

The 3 stratification classifications enabled satisfactory risk evaluation of early recurrence in HCC patients with MVI after hepatectomy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zheng Z, Guan R, Jianxi W, et al. Microvascular invasion in hepatocellular carcinoma: a review of its definition, clinical significance, and comprehensive management. J Oncol. 2022;2022:9567041.CrossRef
3.
Feng LH, Sun HC, Zhu XD, et al. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur J Surg Oncol. 2021;47(3):681–9.CrossRef
4.
Wang H, Wu MC, Cong WM. Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis. Hepatol Res. 2019;49(3):344–54.CrossRef
5.
Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220(4):416–27.CrossRef
6.
Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007;13(4):543–51.CrossRef
7.
Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–87.CrossRef
8.
Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis b virus-related hepatocellular carcinoma within the milan criteria. JAMA Surg. 2016;151(4):356–63.CrossRef
9.
Li L, Wu C, Huang Y, Chen J, Ye D, Su Z. Radiomics for the preoperative evaluation of microvascular invasion in hepatocellular carcinoma: a meta-analysis. Front Oncol. 2022;12:831996.CrossRef
10.
Li Y, Zhang Y, Fang Q, et al. Radiomics analysis of [(18)F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2021;48(8):2599–614.CrossRef
11.
Xu X, Zhang HL, Liu QP, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019;70(6):1133–44.CrossRef
12.
Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564–71.CrossRef
13.
Shirabe K, Toshima T, Kimura K, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 2014;34(6):937–41.CrossRef
14.
Feng LH, Dong H, Lau WY, et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143(2):293–303.CrossRef
15.
Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–5.CrossRef
16.
17.
Iguchi T, Shirabe K, Aishima S, et al. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation. Transplantation. 2015;99(6):1236–42.CrossRef
18.
Zhao H, Chen C, Fu X, et al. Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection. Oncotarget. 2017;8(3):5474–86.CrossRef
19.
Wang K, Xiang YJ, Yu HM, et al. A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion. Eur J Surg Oncol. 2021;48:1348–55.CrossRef
20.
Chen ZH, Zhang XP, Feng JK, et al. Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China. Hepatol Int. 2021;15(3):642–50.CrossRef
21.
Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63.CrossRef
22.
Wang TL, Liu X, Zhou YP, He JW, Zhang J, Li NZ, Duan ZP, Wang BE. A semiquantitative scoring system for assessment of hepatic inflammation and fibrosis in chronic viral hepatitis. Chin J Hepatol. 1998;6(4):195–7.
23.
Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47(5):684–90.CrossRef
24.
Hoshida Y, Villanueva A, Sangiovanni A, et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology. 2013;144(5):1024–30.CrossRef
25.
26.
27.
28.
29.
30.
Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–63.CrossRef
31.
Xue X, Liao W, Xing Y. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma. Infect Agent Cancer. 2020;15:11.CrossRef
32.
Kokudo N, Takemura N, Kanto T, Tateishi R, Igari T, Hasegawa K. Hepatocellular carcinoma with non-B and non-C hepatitis origin: epidemiology in Japan and surgical outcome. Glob Health Med. 2019;1(1):23–9.CrossRef
33.
Utsunomiya T, Shimada M, Kudo M, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2015;261(3):513–20.CrossRef
34.
35.
Lau WY, Wang K, Zhang XP, et al. A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus. Hepatobiliary Surg Nutr. 2021;10(6):782–95.CrossRef
36.
Wong TC, Lee VH, Law AL, et al. Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology. 2021;74(5):2580–94.CrossRef
37.
Chotirosniramit A, Liwattanakun A, Junrungsee S, Ko-Iam W, Sandhu T, Lapisatepun W. The benefit of curative liver resection with a selective bile duct preserving approach for hepatocellular carcinoma with macroscopic bile duct tumor thrombus. Hepatobiliary Surg Nutr. 2020;9(6):729–38.CrossRef
38.
Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol. 2020;6(2):255–63.CrossRef
39.
Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China. Liver Cancer. 2018;7(3):235–60.CrossRef
40.
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–93.CrossRef
41.
Metadaten
Titel
A Practical Risk Classification of Early Recurrence in Hepatocellular Carcinoma Patients with Microvascular invasion after Hepatectomy: A Decision Tree Analysis
verfasst von
Long-Hai Feng, MD, PhD
Yu-Yao Zhu, MD, MM
Jia-Min Zhou, MD, PhD
Miao Wang, MD, MM
Lei Wang, MD, PhD
Wei-Qi Xu, MD, PhD
Ti Zhang, MD, PhD
An-Rong Mao, MD, PhD
Wen-Ming Cong, MD, PhD
Hui Dong, MD, PhD
Lu Wang, MD, PhD
Publikationsdatum
23.09.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2023
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12598-7

Weitere Artikel der Ausgabe 1/2023

ASO Visual Abstract: Is Total Omentectomy Mandatory in T3 and T4a Gastric Cancer for Laparoscopic Distal Gastrectomy?

  • ASO Visual Abstract

ASO Visual Abstract: Proof of Principle of Combining Fluorescence-Guided Surgery with Photoimmunotherapy to Improve the Outcome of Pancreatic Cancer Therapy in an Orthotopic Mouse Model

  • ASO Visual Abstract

Axillary Staging Is Not Justified in Postmenopausal Clinically Node-Negative Women Based on Nodal Disease Burden

  • Breast Oncology

Screening MRI in Patients with High-Risk Breast Lesions: More May Not Necessarily be More

  • Breast Oncology

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

  • Melanoma

ASO Author Reflections: Evaluation of the Longitudinal Changes in the Systemic Inflammatory Response of Patients With Hepatocellular Carcinoma

  • ASO Author Reflections

Neu im Fachgebiet Chirurgie

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Op.-Entscheidung bei Divertikulitis: Lebensqualität zählt!

Soll man Menschen, die schon mehrfach schmerzhafte Divertikulitisepisoden durchgemacht haben, eine Op. anbieten? Ein Team aus Helsinki rät, dies von der Lebensqualität abhängig zu machen.

Akute Cholezystitis bei multimorbiden Älteren: Operation nicht sofort ausschließen!

Bei älteren, multimorbiden Menschen mit akuter Cholezystitis wird eine Operation häufig nicht erwogen. Eine Studie aus Philadelphia zeigt nun jedoch, dass auch diese Patientinnen und Patienten von einer chirurgischen Therapie profitieren können.

Was geschehen muss, damit Prähabilitation in die Leitlinien kommt

Eine Prähabilitation vor einem viszeralchirurgischen Eingriff ist Experten zufolge äußerst sinnvoll, dennoch wird sie in Leitlinien derzeit nicht empfohlen. Beim DCK erklärte Prof. Tim Vilz aus Bonn, woran das liegt und was benötigt wird, um die Situation zu ändern.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise